(AOF) – Illumina announced on Friday that it would sell the cancer screening test manufacturer Grail in 12 months, under the terms of the European Commission’s order, in the event of failure of its appeal to the CJEU ( Court of Justice of the European Union). The American group maintains that the Brussels Commission “is not competent” to judge this acquisition. The $7.1 billion deal was rejected by Brussels because Illumina would have an interest in preventing Grail’s rivals from accessing its technology.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
